Endogenous GLP-1 Helps Control Blood Fat Levels After Eating in Type 2 Diabetes | Research

The takeaway

Blocking the body's natural GLP-1 signaling with exendin(9-39) significantly increased blood triglycerides after fat intake in people with type 2 diabetes, proving that endogenous GLP-1 plays a direct role in managing postprandial lipid levels.

Total TGs increased P<0.001 when GLP-1 blocked
Exendin(9-39) blockade of endogenous GLP-1 during vildagliptin treatment revealed GLP-1's direct role in controlling postprandial triglycerides

What the researchers found

Vildagliptin (a DPP-4 inhibitor that preserves endogenous GLP-1) selectively reduced two triglyceride species — TG(54:4) and TG(54:5) — during intraduodenal fat infusion (each P < 0.01), without significantly affecting total triglycerides.

Critically, when endogenous GLP-1 signaling was blocked with exendin(9-39) during vildagliptin treatment, plasma total triglycerides increased significantly (P < 0.001), along with elevations in 10 individual triglyceride species (P < 0.05 each). This reversal upon GLP-1 blockade provides direct evidence that endogenous GLP-1 contributes to physiological regulation of postprandial triglyceride appearance in type 2 diabetes.

Why it matters

While GLP-1 receptor agonist drugs (like semaglutide) are known to improve lipid profiles, it wasn't clear whether the body's own GLP-1 does the same thing. This study proves it does — endogenous GLP-1 actively helps control blood fat levels after eating. This matters because it suggests that even modest increases in natural GLP-1 (through diet, DPP-4 inhibitors, or other means) could provide meaningful lipid-lowering benefits, and it deepens our understanding of why GLP-1 drugs reduce cardiovascular risk.

How the study worked

Fifteen participants with type 2 diabetes (managed by diet and/or metformin) were studied in a double-blind, randomized, crossover design across three visits. Vildagliptin (50 mg) or placebo was given orally 60 minutes before fat infusion. On one vildagliptin day, the GLP-1 receptor blocker exendin(9-39) was infused intravenously. A lipid emulsion was infused directly into the duodenum (2 kcal/min for 120 minutes), followed by a mixed meal. Plasma triglycerides were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for detailed individual species analysis.

What this study cannot tell us

Small sample size (n=15) limits generalizability. Only participants with diet/metformin-managed T2D were studied — results may differ in more advanced diabetes or with insulin therapy. The study used intraduodenal lipid infusion rather than normal eating, which doesn't fully replicate physiological meal ingestion. The study measured acute postprandial effects; chronic lipid-lowering effects of enhanced GLP-1 were not assessed. Only vildagliptin was tested, so results may not apply to all DPP-4 inhibitors equally.

How to read the evidence

This is a double-blind, randomized crossover study in humans — a strong design where each participant serves as their own control. The use of exendin(9-39) to specifically block GLP-1 signaling provides mechanistic evidence beyond simple correlation. However, the small sample size (n=15) and acute single-meal design limit the evidence for long-term clinical outcomes.

When this study was published

Published in 2026, this is a very recent study providing the latest mechanistic insights into GLP-1's role in lipid metabolism, highly relevant to the rapidly evolving field of incretin-based therapies.

The bigger picture

This study adds a crucial mechanistic piece to the GLP-1 story. The cardiovascular benefits of GLP-1 receptor agonists have been attributed to multiple factors, but the specific role of GLP-1 in lipid metabolism has been unclear. Demonstrating that endogenous GLP-1 directly modulates postprandial triglycerides connects GLP-1 biology to lipid-driven cardiovascular risk — a finding with implications for understanding both natural metabolic regulation and why GLP-1-based therapies protect the heart.

Questions still open

Does long-term enhancement of endogenous GLP-1 through DPP-4 inhibitors translate to sustained improvements in lipid profiles and cardiovascular risk?
How does the lipid-modulating effect of endogenous GLP-1 compare quantitatively to that of pharmacological GLP-1 receptor agonists?
Could dietary strategies that boost natural GLP-1 release provide meaningful triglyceride-lowering benefits in people with type 2 diabetes?

Common questions

What is endogenous GLP-1 and how is it different from GLP-1 drugs?

Endogenous GLP-1 is the glucagon-like peptide-1 naturally produced by your gut after eating. It helps regulate blood sugar, appetite, and (as this study shows) blood fat levels. GLP-1 drugs like semaglutide are synthetic versions that last much longer in the body. This study focused on the natural version to understand its baseline role in lipid metabolism.

How did researchers prove that GLP-1 was responsible for the lipid effects?

They used exendin(9-39), a peptide that specifically blocks the GLP-1 receptor. When they enhanced natural GLP-1 with vildagliptin but then blocked its signaling with exendin(9-39), blood triglycerides rose significantly. This 'block and measure' approach is strong evidence that GLP-1 was directly responsible for keeping triglycerides lower.

Read the original research

Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.

Diabetes

View on PubMed ↗Publisher’s paper ↗

Citation

Xie, Cong; White, Jake B; Huang, Weikun; Horowitz, Michael; Rayner, Christopher K; Verjans, Johan W; Snel, Marten F; Psaltis, Peter J; Wu, Tongzhi. (2026). Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.. Diabetes. https://doi.org/10.2337/db25-0980